Cited by 371Rheumatoid Arthritis Research and TherapiesInfluenza Virus Research StudiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

van Assen, Sander, Holvast, Albert, Benne, Cornelis A., Posthumus, Marcel D., van Leeuwen, Miek A., Voskuyl, Alexandre E., Blom, Marlies, Risselada, Anke P., de Haan, Aalzen, Westra, Johanna, Kallenberg, Cees G. M., Bijl, Marc·2010·Arthritis & Rheumatism

DOI 10.1002/art.25033

Open this paper in CoChat — free account

Abstract

Objective: For patients with rheumatoid arthritis (RA), yearly influenza vaccination is recommended. However, its efficacy in patients treated with rituximab is unknown. The objectives of this study were to investigate the efficacy of influenza vaccination in RA patients treated with rituximab and to investigate the duration of the possible suppression of the humoral immune response following rituximab treatment. We also undertook to assess the safety of influenza vaccination and the effects of previous influenza vaccination. Methods: Trivalent influenza subunit vaccine was administered to 23 RA patients who had received rituximab (4–8 weeks after rituximab for 11 patients [the early rituximab subgroup] and 6–10 months after rituximab for 12 patients [the late rituximab subgroup]), 20 RA patients receiving methotrexate (MTX), and 29 healthy controls. Levels of antibodies against the 3 vaccine strains were measured before and 28 days after vaccination using hemagglutination inhibition assay. The Disease Activity Score in 28 joints (DAS28) was used to assess RA activity. Results: Following vaccination, geometric mean titers (GMTs) of antiinfluenza antibodies significantly increased for all influenza strains in the MTX‐treated group and in healthy controls, but for no strains in the rituximab‐treated group. However, in the late rituximab subgroup, a rise in GMT for the A/H3N2 and A/H1N1 strains was demonstrated, in the absence of a repopulation of CD19+ cells at the time of vaccination. Seroconversion and seroprotection occurred less often in the rituximab‐treated group than in the MTX‐treated group for the A/H3N2 and A/H1N1 strains, while seroprotection occurred less often in the rituximab‐treated group than in the healthy controls for the A/H1N1 strain. Compared with unvaccinated patients in the rituximab‐treated group, previously vaccinated patients in the rituximab‐treated group had higher pre‐ and postvaccination GMTs for the A/H1N1 strain. The DAS28 did not change after vaccination. Conclusion: Rituximab reduces humoral responses following influenza vaccination in RA patients, with a modestly restored response 6–10 months after rituximab administration. Previous influenza vaccination in rituximab‐treated patients increases pre‐ and postvaccination titers. RA activity was not influenced.

Integrity signals

Registry

Crossref · 10.1002/art.25033

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,742
Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 999
T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly
McElhaney, J. E., Xie, D., Hager, W. D., Barry, M. B., Wang, Y., Kleppinger, A., Ewen, C., Kane, K. P., & Bleackley, R. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6333 · Cited by 561
Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis
Roll, P., Palanichamy, A., Kneitz, C., Dörner, T., & Tony, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22019 · Cited by 321
Haemagglutination-inhibiting antibody to influenza virus.
de Jong, J. C., Palache, A. M., BEYER, W. E. P., Rimmelzwaan, G. F., Boon, A. C. M., & Osterhaus, A. D. M. E. (2003) · PubMed · Cited by 319
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
Фомин, И. Н., Caspi, D., Levy, V., Varsano, N., Shalev, Y., Paran, D., Levartovsky, D., Litinsky, I., Kaufman, I., Wigler, I., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.036434 · Cited by 266
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
Oren, S., Mandelboim, M., Braun‐Moscovici, Y., Paran, D., Ablin, J. N., Litinsky, I., Comaneshter, D. S., Levartovsky, D., Mendelson, E., Azar, R., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.077461 · Cited by 242

Flagged first, then by citations

Show all 18 references

Sorted by citations

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
“Specifically, influenza vaccination did not increase disease activity in patients with SLE or RA [100, 101, 451, 453, 470–472].”
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Furer, V., Rondaan, C., Heijstek, M. W., Agmon‐Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 859
Self-citation
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., Zisapel, M., Elalouf, O., Kaufman, I., Meidan, R., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220647 · Cited by 654
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Fürst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., Benedetti, F. D., Dorner, T. E., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 688
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
van Assen, S., Agmon‐Levin, N., Elkayam, O., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137216 · Cited by 631
Self-citation
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 506
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G. R., Dörner, T., Ferraccioli, G., Gottenberg, J., Isaacs, J. D., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 457
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
Deepak, P., Kim, W., Paley, M., Yang, M. M., Carvidi, A. B., Demissie, E., El‐Qunni, A. A., Haile, A., Huang, K., Kinnett, B., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1757 · Cited by 424
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis
Bar‐Or, A., Calkwood, J., Chognot, C., Evershed, J., Fox, E., Herman, A. E., Manfrini, M., McNamara, J., Robertson, D. S., Stokmaier, D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010380 · Cited by 339
Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs
Bykerk, V. P., Akhavan, P. S., Hazlewood, G. S., Schieir, O., Dooley, A., Haraoui, B. P., Khraishi, M. M., LECLERCQ, S. A., Legare, J. F., Mosher, D., et al. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110207 · Cited by 335
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
Seto, W., Chan, T. S. Y., Hwang, Y., Wong, D. K.-H., Fung, J., Liu, K. S.-H., Gill, H., Lam, Y.-F., Lie, A. K. W., Lai, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7081 · Cited by 331
“Although HBV vaccination before rituximab therapy could also be considered,(31) the need for rapid chemotherapy initiation on diagnosis, the reduced humoral response during rituximab therapy, and the possible need for booster vaccines to achieve a sustained effect would hinder its execution.(32,33) For antiHBs–positiv…”
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Hill, J. A., & Seo, S. K. (2020) · Blood · doi:10.1182/blood.2019004000 · Cited by 320
Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis
Hua, C., Barnetche, T., Combe, B., & Morel, J. (2014) · Arthritis Care & Research · doi:10.1002/acr.22246 · Cited by 287
Memory B and memory plasma cells
Yoshida, T., Mei, H. E., Dörner, T., Hiepe, F., Radbruch, A., Fillatreau, S., & Hoyer, B. F. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00938.x · Cited by 301
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
Prendecki, M. F., Clarke, C., Edwards, H., McIntyre, S., Mortimer, P. M., Gleeson, S., Martin, P., Thomson, T., Randell, P. A., Shah, A., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220626 · Cited by 238
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Mrak, D., Tobudic, S., Koblischke, M., Graninger, M., Radner, H., Sieghart, D., Hofer, P., Perkmann, T., Haslacher, H., Thalhammer, R., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220781 · Cited by 241
American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Sadun, R. E., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41734 · Cited by 240
B‐cell targeted therapies in human autoimmune diseases: an updated perspective
Townsend, M. J., Monroe, J. G., & Chan, A. C. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00945.x · Cited by 240
“In contrast to assessing the effects of immunization administered immediately before the initiation of B cell depletion, a second study addressed the effectiveness of early (4–8 weeks) versus late (6–10 months) immunization with trivalent influenza vaccine after patients were treated with rituximab (145).”
Background
EULAR recommendations for vaccination in paediatric patients with rheumatic diseases
Heijstek, M. W., de Bruin, L. M. O., Bijl, M., Borrow, R., van der Klis, F. R. M., Koné‐Paut, I., Fasth, A. L., Minden, K., Ravelli, A., Abinun, M., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.150193 · Cited by 225
Self-citation
Does rituximab increase the incidence of infectious complications? A narrative review
Kelesidis, T., Daikos, G. L., Boumpas, D. T., & Tsiodras, S. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.03.025 · Cited by 222
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees
Otani, I. M., Lehman, H. K., Jongco, A. M., Tsao, L. R., Azar, A., Tarrant, T. K., Engel, E. R., Walter, J. E., Truong, T. Q., Khan, D. A., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.025 · Cited by 228
“Braun WE, Avery R, Gifford RW, Straffon RA.”
BackgroundInfluential
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Leandro, M. J. (2013) · Arthritis Research & Therapy · doi:10.1186/ar3908 · Cited by 214
Vaccinations in patients with immune-mediated inflammatory diseases
Rahier, J. F., Moutschen, M. P., Gompel, A. V., Ranst, M. A. V., Louis, E. J., Segaert, S., Masson, P., & Keyser, F. D. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq183 · Cited by 200
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41928 · Cited by 200
“The rationale for this recommendation comes from a single study demonstrating minimal response to influenza vaccination in 11 patients vaccinated 4– 8 weeks after RTX treatment, with modestly restored responses in patients vaccinated 6– 10 months after their last RTX dose (65).”
Background
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Grainger, R., Kim, A. H. J., Conway, R. P., Yazdany, J., & Robinson, P. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00755-x · Cited by 193
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Spiera, R., Jinich, S., & Jannat-Khah, D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220604 · Cited by 180
Rituximab for the treatment of rheumatoid arthritis: an update
Mok, C. C. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41645 · Cited by 177
Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations
Kumar, D., Blumberg, E. A., Danziger‐Isakov, L. A., Kotton, C. N., Halasa, N., Ison, M. G., Avery, R. K., Green, M., Allen, U., Edwards, K. M., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03753.x · Cited by 176
“There are no published data on the effects of rituximab on vaccine responses in solid organ transplantation; extrapolation from studies in patients with rheumatologic disorders suggests that responses are diminished but not abrogated (46).”
Background
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Seze, J. D., Maillart, É., Guéguen, A., Laplaud, D. A., Michel, L., Thouvenot, É., Zéphir, H., Zimmer, L., Biotti, D., & Liblau, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1004795 · Cited by 169
Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
Rondaan, C., Furer, V., Heijstek, M. W., Agmon-Levin, N., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., van Laar, J. M., et al. (2019) · RMD Open · doi:10.1136/rmdopen-2019-001035 · Cited by 154
“A study that included both patients with RA vaccinated 4–8 weeks (n=11) and 6–10 months after (n=12) the administration of rituximab demonstrated no response to influenza vaccination in the first, early group and a modestly restored response in the late group.(14) The use of rituximab did not seem”
BackgroundSelf-citation
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
Perry, C., Luttwak, E., Balaban, R., Shefer, G., Morales, M., Aharon, A., Tabib, Y., Cohen, Y. C., Benyamini, N., Beyar‐Katz, O., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005094 · Cited by 153
“…in line with those of prior studies 20 – 22 in which R signi ﬁ cantly attenuated response to vaccines, aimed at various pathogens (eg, in ﬂ uenza 23 and hepatitis 24 ), for at least 6 months after completion of treat-ment 13,22 and support recommendations to vaccinate patients with B-cell…”
Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases
van Assen, S., Elkayam, O., Agmon‐Levin, N., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.12.003 · Cited by 145
Self-citation
Seasonal influenza vaccine in immunocompromised persons
Bosaeed, M., & Kumar, D. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1445446 · Cited by 145
Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
Crnkic Kapetanovic, M., Saxne, T., Jönsson, G., Truedsson, L., & Geborek, P. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4358 · Cited by 142
“no significant correlation between timing of vaccination in relation to administration of rituximab was found in our study [9].”
Result
Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes
Makatsori, M., Kiani‐Alikhan, S., Manson, A. L., Verma, N., Leandro, M. J., Gurugama, N. P., Longhurst, H. J., Grigoriadou, S., Buckland, M. S., Kanfer, E., et al. (2014) · QJM · doi:10.1093/qjmed/hcu094 · Cited by 144
T cell-independent B cell memory
Defrance, T., Taillardet, M., & Genestier, L. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.004 · Cited by 142
Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1
Bozic, C. M., Richman, S., Plavina, T., Natarajan, A., Scanlon, J. V., Subramanyam, M., Sandrock, A. W., & Bloomgren, G. (2011) · Annals of Neurology · doi:10.1002/ana.22606 · Cited by 142
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study
Gabay, C., Bel, M., Combescure, C., Ribi, C., Meier, S., Posfay-Barbe, K. M., Grillet, S., Seebach, J. D., Kaiser, L., Wunderli, W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30325 · Cited by 140
Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety
Bombardier, C., Hazlewood, G. S., Akhavan, P. S., Schieir, O., Dooley, A., Haraoui, B. P., Khraishi, M. M., LECLERCQ, S. A., Legare, J. F., Mosher, D. P., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.120165 · Cited by 137
“Increased risks of malignancy (excluding NMSC) have also not been reported in RCT/open-label extension studies of ABAT, RTX, and TCZ 27,94,95 , although data from population registries with longer followup are currently unavailable.”
Background
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab
Mei, H. E., Frölich, D., Giesecke‐Thiel, C., Loddenkemper, C., Reiter, K., Schmidt, S., Feist, E., Daridon, C., Tony, H., Radbruch, A., et al. (2010) · Blood · doi:10.1182/blood-2010-01-266536 · Cited by 133
The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab
Arad, U., Tzadok, S., Amir, S., Mandelboim, M., Mendelson, E., Wigler, I., Sarbagil‐Maman, H., Paran, D., Caspi, D., & Elkayam, O. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.072 · Cited by 132
Rituximab-treated patients have a poor response to influenza vaccination
Eisenberg, R. A., Jawad, A. F., Boyer, J., Maurer, K., McDonald, K., Prak, E. T. L., & Sullivan, K. E. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9813-x · Cited by 126
“Some studies have found an association of vaccine responses with the degree of B cell depletion [37, 43, 47] while others have not found such an association [36, 38, 39].”
Background
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies
Papp, K. A., Haraoui, B. P., Kumar, D., Marshall, J. K., Bissonnette, R., Bitton, A., Bressler, B. L., Gooderham, M., HO, V. C., Jamal, S., et al. (2018) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475418811335 · Cited by 124
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
Fürst, D. E., Keystone, E. C., Braun, J. M., Fc, B., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201036 · Cited by 122
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
Friedman, M., Curtis, J. R., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221244 · Cited by 126
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
Fürst, D. E., Keystone, E. C., So, A. K.-L., Braun, J., Breedveld, F. C., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203348 · Cited by 120
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Keyser, F. D. (2011) · Current Rheumatology Reviews · doi:10.2174/157339711794474620 · Cited by 124
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Mei, H. E., Schmidt, S., & Dörner, T. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3909 · Cited by 121
A comprehensive review of rituximab therapy in rheumatoid arthritis patients
Tavakolpour, S., Alesaeidi, ‬., Darvishi, M., Ghasemiadl, M., Darabi-Monadi, S., Akhlaghdoust, M., Behjati, S. E., & Jafarieh, A. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04699-8 · Cited by 117
American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42372 · Cited by 129
In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells
Zhang, B., Wang, Y., Yuan, Y., Sun, J., Liu, L., Huang, D., Hu, J., Wang, M., Li, S., Song, W., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217844 · Cited by 116
COVID-19 vaccination and antirheumatic therapy
Arnold, J., Winthrop, K. L., & Emery, P. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab223 · Cited by 114
“B-cell depleting therapy has been shown to impair humoral responses to the influenza and pneumococcal vaccines in several studies and a subsequent meta-analysis(6,15,30,31).”
Background
Adverse reactions to biologic agents and their medical management
Boyman, O., Comte, D., & Spertini, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.123 · Cited by 117
A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis
Subesinghe, S., Bechman, K., Rutherford, A. I., Goldblatt, D., & Galloway, J. B. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170710 · Cited by 110
“poorer serological responses to immunisation,[15, 22, 26, 37, 38].”
Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
Saad, C. G. S., Borba, E. F., Aikawa, N. E., Silva, C. A., Pereira, R. M. R., Calich, A. L., de Moraes, J. C. B., Ribeiro, A. C. D. M., Viana, V. S. T., Pasoto, S. G., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.150250 · Cited by 109
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna, B., Kennedy, N. A., Mehrkar, A., Rowan, A., Galloway, J. B., Matthewman, J., Mansfield, K. E., Bechman, K., Yates, M., Brown, J. P., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00098-4 · Cited by 112
B cell checkpoints in autoimmune rheumatic diseases
Rubin, S. J. S., Bloom, M. S., & Robinson, W. H. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0211-0 · Cited by 109
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients
Vijenthira, A., Gong, I. Y., Betschel, S., Cheung, M. C., & Hicks, L. K. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004629 · Cited by 108
“35 Studies were small and contradictory in their ﬁ ndings with respect to whether T-cell immunity was preserved or diminished following anti-CD20 therapy.”
American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41877 · Cited by 108
“The rationale for this recommendation comes from a single study demonstrating minimal response to influenza vaccination in 11 patients vaccinated 4– 8 weeks after RTX treatment, with modestly restored responses in patients vaccinated 6– 10 months after their last RTX dose (65).”
Background
Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing Regimens
Bedognetti, D., Zoppoli, G. M., Massucco, C., Zanardi, E., Zupo, S., Bruzzone, A., Sertoli, M. R., Balleari, E., Racchi, O., Messina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004095 · Cited by 106
Frequency, risk factors and prophylaxis of infection in ANCA ‐associated vasculitis
Kronbichler, A., Jayne, D. R. W., & Mayer, G. J. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12410 · Cited by 105
Rituximab for Rheumatoid Arthritis
Cohen, M. D., & Keystone, E. C. (2015) · Rheumatology and Therapy · doi:10.1007/s40744-015-0016-9 · Cited by 105
Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study
Adler, S., Krivine, A., Weix, J., Rozenberg, F., Launay, O., Huesler, J., Guillevin, L., & Villiger, P. M. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker389 · Cited by 101
Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults
McAtee, C. L., Lubega, J., Underbrink, K., Curry, K., Msaouel, P., Barrow, M., Muscal, E., Lotze, T. E., Srivaths, P. R., Forbes, L. R., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36321 · Cited by 103
Vaccination against infection in patients with multiple sclerosis
Loebermann, M., Winkelmann, A., Hartung, H., Hengel, H., Reisinger, E. C., & Zettl, U. K. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.8 · Cited by 102
Current perspective on rituximab in rheumatic diseases
Schioppo, T., & Ingegnoli, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s139248 · Cited by 98
“For this reason, the better results in terms of humoral response are reported 6 months or more after RTX dosing.(112,113) Vaccinations should be considered at least 4 weeks before RTX administration.”
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Zheng, C. Y., Kar, I., Chen, C. K., Sau, C., Woodson, S., Serra, A., & Abboud, H. (2020) · CNS Drugs · doi:10.1007/s40263-020-00756-y · Cited by 99
Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial
Chatham, W. W., Wallace, D. J., Stohl, W., Latinis, K. M., Manzi, S., McCune, W. J., Tegzová, D., McKay, J. D., Armengol, H. Á., Utset, T. O., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111587 · Cited by 95
Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients
Westra, J., van Assen, S., Wilting, K. R., Land, J., Horst, G., de Haan, A., & Bijl, M. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12390 · Cited by 92
Self-citation
Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases
Bühler, S., Éperon, G., Ribi, C., Kyburz, D., van Gompel, F., Visser, L. G., Siegrist, C., & Hatz, C. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14159 · Cited by 92
Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases
Elkayam, O., Sharon, A., Mendelson, E., Schwaber, M. J., Grotto, I., Wollman, J., Arad, U., Brill, A., Paran, D., Levartovsky, D., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20465 · Cited by 91
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity
Murdaca, G., Orsi, A., Spanò, F. M., Puppo, F., Durando, P., Icardi, G., & Ansaldi, F. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.07.007 · Cited by 87
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis
Kapetanovic, M. C., Kristensen, L., Saxne, T., Aktas, T., Mörner, A., & Geborek, P. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4427 · Cited by 81
Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series
Roberts, D. M., Jones, R. B., Smith, R., Alberici, F., Kumararatne, D. S., Burns, S., & Jayne, D. R. W. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.11.004 · Cited by 79
Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial
Kivitz, A., Schechtman, J., Texter, M. J., Fichtner, A., Longueville, M. D., & Chartash, E. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130945 · Cited by 79
Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study
Rousseau, B., Loulergue, P., Mir, O., Krivine, A., Kotti, S., Viel, E., Simon, T., de Gramont, A., Goldwasser, F., Launay, O., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr141 · Cited by 77
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Alten, R., Bingham, C. O., Cohen, S. B., Curtis, J. R., Kelly, S., Wong, D., & Genovese, M. C. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1082-z · Cited by 75
“Additionally, vaccination with the PPSV23 and influenza vaccines was well tolerated by patients with RA treated with abatacept, and these results are consistent with other vaccination studies in patients receiving biologic therapies, specifically rituximab, adalimumab, and tocilizumab [1, 26, 27, 30, 35].”
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
Louapre, C., Ibrahim, M., Maillart, É., Abdi, B., Papeix, C., Stankoff, B., Dubessy, A., Bensa, C., Créange, A., Chamekh, Z., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326904 · Cited by 74
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
Rehnberg, M., Brisslert, M., Amu, S., Zendjanchi, K., Håwi, G., & Bokarewa, M. I. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3047 · Cited by 75
Immunization in the adult immunocompromised host
Löbermann, M., Boršo, D., Hilgendorf, I., Fritzsche, C., Zettl, U. K., & Reisinger, E. C. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.05.015 · Cited by 71
“However, reduced immunogenicity has been described in SLE [12] or RA [13] for influenza vaccines and for the Hepatitis B vaccine, even when patients were not undergoing immunosuppressive therapy [14].”
BackgroundResult
Vaccination of patients with autoimmune inflammatory rheumatic diseases
Westra, J., Rondaan, C., van Assen, S., & Bijl, M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.206 · Cited by 72
Self-citation
Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides
Charles, P., Bienvenu, B., Bonnotte, B., Gobert, P., Godmer, P., HACHULLA, E., Hamidou, M. A., Harlé, J., Karras, A., Lega, J., et al. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.08.003 · Cited by 71
“The immune response is partially restored 6 to 10 months after the end of treatment [49,50], suggesting that vaccination under treatment should preferably be postponed to some later date.”
BackgroundInfluential
American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42109 · Cited by 69
Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab
Cho, A., Bradley, B., Kauffman, R. C., Priyamvada, L., Kovalenkov, Y. O., Feldman, R. J., & Wrammert, J. (2017) · JCI Insight · doi:10.1172/jci.insight.93222 · Cited by 68
Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children
Davies, H. D., Byington, C. L., Maldonado, Y., Barnett, E. D., Edwards, K. M., Lynfield, R., Muñoz, F. M., Nolt, D. L., Nyquist, A., Rathore, M. H., et al. (2016) · PEDIATRICS · doi:10.1542/peds.2016-1209 · Cited by 66
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement
Riva, A., Barcella, V., Benatti, S. V., Capobianco, M. A. N., Capra, R., Cinque, P. M., Comi, G., Fasolo, M., Franzetti, F., Galli, M., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520952310 · Cited by 66
Impact of host genetic polymorphisms on vaccine induced antibody response
Linnik, J., & Egli, A. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1119345 · Cited by 65
Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment
Bijl, M., Agmon‐Levin, N., Dayer, J.-M., Israeli, E., Gatto, M., & Shoenfeld, Y. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.015 · Cited by 62
Self-citation
Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
Kim, W., Kim, S. H., Huh, S., Kong, S., Choi, Y. J., Cheong, H. J., & Kim, H. J. (2013) · European Journal of Neurology · doi:10.1111/ene.12132 · Cited by 62
“This is especially a question of concern for patients treated with rituximab, a chimeric monoclonal antibody against the human CD20 molecule, because this drug particularly affects humoral immune responses [3], which are an important component of vaccination-mediated protection.”
Background
Influenza Vaccination for Immunocompromised Patients: Systematic Review and Meta-Analysis from a Public Health Policy Perspective
Beck, C., McKenzie, B. C., Hashim, A. B., Harris, R. C., Zanuzdana, A., Agboado, G., Orton, E., Béchard‐Evans, L., Morgan, G. S., Stevenson, C. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029249 · Cited by 62
“After exclusion of multiple reporting (n = 10) 209 individual studies met review eligibility criteria [11,12,36–252]; 16 pertained to vaccines against the 2009 influenza A(H1N1) pandemic virus [39,43,48,55,79,86,104, 170,181,188,212,223–225,232,243].”
Vaccines and Disease-Modifying Antirheumatic Drugs
Friedman, M., & Winthrop, K. L. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.003 · Cited by 60
Nanomedicine for the Treatment of Rheumatoid Arthritis
Jeong, M., & Park, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00295 · Cited by 60
Suppression of normal immune responses after treatment with rituximab
Kado, R., Sanders, G., & McCune, W. J. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000272 · Cited by 60
“The impairment was most notable when vaccination was administered at 4–8 weeks instead of 6–10 months after rituximab therapy [41].”
Background
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
Ghanima, W., Gernsheimer, T., & Kuter, D. J. (2021) · Blood · doi:10.1182/blood.2021010968 · Cited by 58
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
Rempe, T. J., & Harel, A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102341 · Cited by 57
Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?
Worch, J., Makarova, O., & Burkhardt, B. (2015) · Cancers · doi:10.3390/cancers7010305 · Cited by 57
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions
Krasselt, M., Wagner, U. G., Nguyen, P., Pietsch, C., Boldt, A., Baerwald, C., Pierer, M., & Seifert, O. (2022) · Rheumatology · doi:10.1093/rheumatology/keac089 · Cited by 57
Rituximab for immunologic renal disease: What the nephrologist needs to know
Kronbichler, A., Windpessl, M., Pieringer, H., & Jayne, D. R. W. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.007 · Cited by 55
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
Walti, C. S., Loes, A. N., Shuey, K. D., Krantz, E. M., Boonyaratanakornkit, J. B., Keane-Candib, J., Loeffelholz, T., Wolf, C. R., Taylor, J. J., Gardner, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003428 · Cited by 57

Authors: van Assen, S., Holvast, A., Benne, C. A., Posthumus, M. D., van Leeuwen, M. A., Voskuyl, A. E., Blom, M., Risselada, A. P., de Haan, A., Westra, J., Kallenberg, C. G. M., & Bijl, M.
Affiliations: University Medical Center Groningen (NL)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Radboud University Nijmegen (NL)
University Medical Center Utrecht (NL)
ORCID: Voskuyl, Alexandre E.
Westra, Johanna
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 2009-12-28
Volume: 62
Issue: 1
Pages: 75-81
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.25033
OpenAlex: W2059903231
Cited by: 371
References: 18
Citations by year: 2026: 11 · 2025: 9 · 2024: 21 · 2023: 20 · 2022: 35 · 2021: 57 · 2020: 30 · 2019: 11 · 2018: 17 · 2017: 14 · 2016: 14 · 2015: 20 · 2014: 23 · 2013: 24 · 2012: 15
FWCI: 15.33
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: rheumatoid arthritis, rituximab, influenza vaccination, humoral immune response, influenza antibodies, seroprotection, seroconversion, methotrexate, CD19+ B cells, vaccine efficacy, disease activity, trivalent influenza vaccine, B-cell depletion, hemagglutination inhibition test, DAS28
MeSH terms: Rituximab, Antibodies, Monoclonal, Antibodies, Viral, Arthritis, Rheumatoid, Drug Therapy, Combination, Female, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Immunologic Memory, Influenza Vaccines, Male, Methotrexate, Middle Aged, Vaccines, Inactivated, B-Lymphocyte Subsets, Antirheumatic Agents, Antigens, CD20, Immunity, Humoral, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks